Pulleyblank, Ryan http://orcid.org/0000-0002-1129-8215
Larsen, Nikolaj Birk
Clinical trials referenced in this document:
Documents that mention this clinical trial
670-P: Time Spent in Glycemic Control after Initiating Treatment with Oral Semaglutide vs. Empagliflozin: An Exploratory Analysis of the PIONEER 2 Trial
https://doi.org/10.2337/db21-670-p
1163-P: Cost Effectiveness of Oral Semaglutide 14mg vs. Empagliflozin 25mg in Canada
https://doi.org/10.2337/db20-1163-p
54-OR: Oral Semaglutide vs. Empagliflozin Added On to Metformin Monotherapy in Uncontrolled Type 2 Diabetes: PIONEER 2
https://doi.org/10.2337/db19-54-or
Cost-Effectiveness of Semaglutide vs. Empagliflozin, Canagliflozin, and Sitagliptin for Treatment of Patients with Type 2 Diabetes in Denmark: A Decision-Analytic Modelling Study
https://doi.org/10.1007/s41669-023-00416-z
Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials
https://doi.org/10.1186/s12933-022-01585-7
Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial (Results)
https://doi.org/10.2337/dc19-0883
Documents that mention this clinical trial
Oral Semaglutide Reduces HbA1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Glucose-Lowering Medication: PIONEER Subgroup Analyses
https://doi.org/10.1007/s13300-020-00994-9
Cost-Effectiveness of Semaglutide vs. Empagliflozin, Canagliflozin, and Sitagliptin for Treatment of Patients with Type 2 Diabetes in Denmark: A Decision-Analytic Modelling Study
https://doi.org/10.1007/s41669-023-00416-z
111-LB: Oral Semaglutide vs. Sitagliptin: Efficacy by Baseline HbA1c and Background OAD in PIONEER 3
https://doi.org/10.2337/db19-111-lb
Documents that mention this clinical trial
Cost-Effectiveness of Semaglutide vs. Empagliflozin, Canagliflozin, and Sitagliptin for Treatment of Patients with Type 2 Diabetes in Denmark: A Decision-Analytic Modelling Study
https://doi.org/10.1007/s41669-023-00416-z
Documents that mention this clinical trial
Cost-Effectiveness of Semaglutide vs. Empagliflozin, Canagliflozin, and Sitagliptin for Treatment of Patients with Type 2 Diabetes in Denmark: A Decision-Analytic Modelling Study
https://doi.org/10.1007/s41669-023-00416-z
Funding for this research was provided by:
Novo Nordisk
Article History
Accepted: 10 April 2023
First Online: 13 May 2023
Declarations
:
: Funded by Novo Nordisk Denmark, Denmark.
: RP and NL are employed by NHTA, which provides consulting services for commercial life-sciences enterprises, including funding from Novo Nordisk.
: All data used in the analyses are available in the article tables and/or online appendices.
: The economic model has been used under licence and is proprietary intellectual property of the Swedish Institute for Health Economics, Lund, Sweden. For access, please contact Sofie Persson at IHE (sofie.persson@ihe.se).
: RP and NL were involved in data extraction, modelling, results interpretation, and creating the manuscript.
: Not applicable.
: Not applicable.
: Not applicable.